ArticleCancer gene therapy2008
Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer.
Article in Cancer gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- Article
- Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment.Cell communication and signaling : CCS · 2023Review
- The Roles of Mesenchymal Stem Cells in Gastrointestinal Cancers.Frontiers in immunology · 2022Review
- A novel approach to genetic engineering of T-cell subsets by hematopoietic stem cell infection with a bicistronic lentivirus.Scientific reports · 2020Article
- Edition of Prostaglandin E2 Receptors EP2 and EP4 by CRISPR/Cas9 Technology in Equine Adipose Mesenchymal Stem Cells.Animals : an open access journal from MDPI · 2020Article
- CSB promoter downregulation via histone H3 hypoacetylation is an early determinant of replicative senescence.Nature communications · 2019Article
- Colony Formation, Migratory, and Differentiation Characteristics of Multipotential Stromal Cells (MSCs) from "Clinically Accessible" Human Periosteum Compared to Donor-Matched Bone Marrow MSCs.Stem cells international · 2019Article
- Non-invasiveOncotarget · 2017Article
- Projection Stereolithographic Fabrication of BMP-2 Gene-activated Matrix for Bone Tissue Engineering.Scientific reports · 2017Article
- Review
- Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells.Oncotarget · 2016Article
- Pancreatic cancer stromal biology and therapy.Genes & diseases · 2015Article
- Deciphering the role of stroma in pancreatic cancer.Current opinion in gastroenterology · 2013Review
- Contribution of bone marrow derived cells to the pancreatic tumor microenvironment.Frontiers in physiology · 2013Article
- Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications.Cytokine & growth factor reviews · 2012Review
- Efficient lentiviral transduction of human mesenchymal stem cells that preserves proliferation and differentiation capabilities.Stem cells translational medicine · 2012Article
- Frontiers in Suicide Gene Therapy of Cancer.Journal of genetic syndromes & gene therapy · 2012Article
- Genetically modified mesenchymal stem cells for improved islet transplantation.Molecular pharmaceutics · 2011Review
- Article
- Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic modification of human bone marrow mesenchymal stem cells (MSC) is highly valuable for their exploitation in basic science and therapeutic applications, for example in cancer. We present here a new, fast and easy-to-use method to enrich a functional population of lentiviral (LV)-transduced MSC expressing enhanced green fluorescent protein (eGFP). We replaced the eGFP gene by a fusion gene of puromycin acetyltransferase and eGFP. Upon LV gene transfer and puromycin selection, we quickly obtained a pure transduced MSC population, in which growth, differentiation capacity and migration preferences were not compromised. Furthermore, we are the first to report the migration velocity of MSC among which 30% were moving and velocity of about 15 mum h(-1) was not altered by LV transduction. Manipulated MSC underwent senescence one passage earlier than non-transduced cells, suggesting the use for therapeutic intervention in early passage numbers. Upon tail vein application in nude mice, the majority of LV-transduced MSC could be detected in human orthotopic pancreatic tumor xenografts and to a minor extent in mouse liver, kidney and lung. Together, LV transduction of genes to MSC followed by puromycin selection is a powerful tool for basic research and improves the therapeutic prospects of MSC as vehicles in gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.